<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
71860-102-01
</NDCCode>
<PackageDescription>
1 SYRINGE, GLASS in 1 CARTON (71860-102-01) / .8 mL in 1 SYRINGE, GLASS
</PackageDescription>
<NDC11Code>
71860-0102-01
</NDC11Code>
<ProductNDC>
71860-102
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Tryngolza
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Olezarsen Sodium
</NonProprietaryName>
<DosageFormName>
INJECTION, SOLUTION
</DosageFormName>
<RouteName>
SUBCUTANEOUS
</RouteName>
<StartMarketingDate>
20260624
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
NDA
</MarketingCategoryName>
<ApplicationNumber>
NDA218614
</ApplicationNumber>
<LabelerName>
Ionis Pharmaceuticals, Inc.
</LabelerName>
<SubstanceName>
OLEZARSEN SODIUM
</SubstanceName>
<StrengthNumber>
50
</StrengthNumber>
<StrengthUnit>
mg/.8mL
</StrengthUnit>
<Pharm_Classes>
APOC-III-directed RNA Interaction [EPC], Antisense Oligonucleotide [EPC], Antisense [CS], Increased RNA Degradation [PE]
</Pharm_Classes>
<DEASchedule/>
<Status>
Active
</Status>
<LastUpdate>
2026-07-06
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20271231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20260624
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>